A Clinical Study on the Effect of Discontinuing Alendronate in Postmenopausal Women with Osteoporosis After a Treatment Period Without Fractures

Last updated: February 28, 2025
Sponsor: Odense University Hospital
Overall Status: Active - Recruiting

Phase

4

Condition

Osteoporosis

Treatment

Alendronate 70mg weekly

Clinical Study ID

NCT06864130
CT 2023-510042-24
2023-510042-24-01
  • Female

Study Summary

The goal of this clinical trial is to study the effects of discontinuation of Alendronate treatment for three years. The participants are postmenopausal women with osteoporosis, who have had a treatment period without fractures. The study will answer:

  • What is the rate of fragility fractures during the study? The hypothesis is that discontinuation of Alendronate after a fracture-free period does not raise the 3-year fracture risk.

  • Are there predictors of significant bone loss after discontinuation of Alendronate? The hypothesis is that clinical, biochemical, cellular, or molecular characteristics can predict bone loss.

Researchers will compare the outcomes of discontinuation of Alendronate with continuing treatment. Participants will be randomly assigned to a group.

Participants will:

  • Either take alendronate once weekly for three years OR discontinue their treatment

  • Visit the clinic at 6 and 18 months for blood samples

  • Visit the clinic at the start of the study and after 1, 2, and 3 years for bone scans and blood samples.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Female

  • Postmenopausal

  • Current treatment with Alendronate

  • Alendronate treatment >3 år AND no fracture OR

  • Alendronate treatment >5 år AND latest low energy fracture > 3 years ago

Exclusion

Exclusion Criteria:

  • T-score < - 3,5 in hip (total hip or femoral neck) or lumbar spine

  • Treatment with systemic glucocorticoids, ongoing or within 12 months

  • Uncontrolled inflammatory disease

  • Active malignancy

  • eGFR < 40 mL/min

  • Atypical femur fracture (ever)

  • OsteoNecrosis of the Jaw (active)

  • Unable to give inform consent

Study Design

Total Participants: 1400
Treatment Group(s): 1
Primary Treatment: Alendronate 70mg weekly
Phase: 4
Study Start date:
February 21, 2025
Estimated Completion Date:
September 15, 2029

Connect with a study center

  • Aalborg University Hospital

    Aalborg, 9000
    Denmark

    Site Not Available

  • Bispebjerg Hospital

    Copenhagen, 2400
    Denmark

    Site Not Available

  • Esbjerg Og Grindsted Sygehus

    Esbjerg, 6700
    Denmark

    Site Not Available

  • Copenhagen University Hospital (Herlev)

    Herlev, 2730
    Denmark

    Site Not Available

  • Nordsjaellands Hospital (Hillerød)

    Hillerød, 3400
    Denmark

    Site Not Available

  • Hvidovre Hospital

    Hvidovre, 2650
    Denmark

    Site Not Available

  • Odense University Hospital

    Odense, 5000
    Denmark

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.